Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells

Experimental Hematology

Volumn 43, Issue 5, 2015, Pages 346-351

  Urbinati, Fabrizia ^a   Hargrove, Phillip W ^b   Geiger, Sabine ^a   Romero, Zulema ^a   Wherley, Jennifer ^a   Kaufman, Michael L ^a   Hollis, Roger P ^a   Chambers, Christopher B ^c   Persons, Derek A ^b   Kohn, Donald B ^a   Wilber, Andrew ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; LENTIVIRUS VECTOR; MESSENGER RNA; HEMOGLOBIN BETA CHAIN;

ARTICLE; BONE MARROW CELL; CASE REPORT; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DEOXYGENATION; ERYTHROBLAST; ERYTHROCYTE DEFORMABILITY; ERYTHROID CELL; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; VIRAL GENE DELIVERY SYSTEM; ANEMIA, SICKLE CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

LENTIVIRUS;

ANEMIA, SICKLE CELL; ANTIGENS, CD34; BETA-GLOBINS; BONE MARROW CELLS; FETAL HEMOGLOBIN; FLOW CYTOMETRY; GAMMA-GLOBINS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMOGLOBINS; HUMANS; LENTIVIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84929047585     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.01.009     Document Type: Article

References (21)

1. Bunn H.F. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997, 337:762-769.
2. Walters M.C. Stem cell therapy for sickle cell disease: Transplantation and gene therapy. Hematology Am Soc Hematol Educ Program 2005, 1:66-73.
3. Stamatoyannopoulos G., Wood W.G., Papayannopoulou T., Nute P.E. A new form of hereditary persistence of fetal hemoglobin in blacks and its association with sickle cell trait. Blood 1975, 46:683-692.
4. Serjeant G.R., Serjeant B.E., Mason K. Heterocellular hereditary persistence of fetal haemoglobin and homozygous sickle-cell disease. Lancet 1977, 1:795-796.
5. Labie D., Pagnier J., Lapoumeroulie C., et al. Common haplotype dependency of high G gamma-globin gene expression and high HbF levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci U S A 1985, 82:2111-2114.
6. Weatherall D.J. The thalassemias. The Molecular Basis for Blood Disorders 2001, 183-226. W.B. Saunders Company, Philadelphia, Penn. G. Stamatoyannopoulos, P. Majerus, R. Perlmutter, H.E. Varmus (Eds.).
7. Powars D.R., Weiss J.N., Chan L.S., Schroeder W.A. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?. Blood 1984, 63:921-926.
8. Bunn H.F. Induction of fetal hemoglobin in sickle cell disease. Blood 1999, 93:1787-1789.
9. Stevens M.C., Hayes R.J., Vaidya S., Serjeant G.R. Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr 1981, 98:37-41.
10. Ngo D.A., Aygun B., Akinsheye I., et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol 2012, 156:259-264.
11. Bunn H.F. Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. Blood 1987, 69:1-6.
12. Levasseur D.N., Ryan T.M., Reilly M.P., McCune S.L., Asakura T., Townes T.M. A recombinant human hemoglobin with antisickling properties greater than fetal hemoglobin. J Biol Chem 2004, 279:27518-27524.
13. Romero Z., Urbinati F., Geiger S., et al. β-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest 2013, 123:3317-3330.
14. + cells following lentiviral vector-mediated gene transfer. Blood 2011, 117:2817-2826.
15. Emery D.W., Yannaki E., Tubb J., Nishino T., Li Q., Stamatoyannopoulos G. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: Flanking with a chromatin insulator reduces gamma-globin silencing invivo. Blood 2002, 100:2012-2019.
16. Ramezani A., Hawley T.S., Hawley R.G. Combinatorial incorporation of enhancer-blocking components of the chicken β-globin 5'HS4 and human T-cell receptor α/δ BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 2008, 26:3257-3266.
17. Hanawa H., Kelly P.F., Nathwani A.C., et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transducer primitive hematopoietic cells from human blood. Mol Ther 2002, 5:242-251.
18. Wilber A., Tschulena U., Hargrove P.W., et al. A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary adult erythroblasts. Blood 2010, 115:3033-3041.
19. Modlich U., Bohne J., Schmidt M., et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108:2545-2553.
20. Sankaran V.G., Menne T.F., Xu J., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842.
21. Samakoglu S., Lisowski L., Budak-Alpdogan T., et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 2006, 24:89-94.